AVBP — ArriVent BioPharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1868279 ·
Last close
$10.69
Market Cap
$552.92M
52W High
$35.83
52W Low
$10.49
ADV30
1,513,685
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -48,376,000 | -45,313,000 | 417,089,000 | 113,583,000 | 23,613,000 |
| Jun 2026 | 0 | — | -52,691,000 | -49,893,000 | 394,718,000 | 154,682,000 | 27,877,000 |
| Mar 2026 | 0 | — | -46,111,000 | -43,320,000 | 349,295,000 | 62,103,000 | 25,315,000 |
| Dec 2025 | 0 | — | -38,823,000 | -35,544,000 | 333,169,000 | 45,540,000 | 25,945,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-152,841,000
Investing CF
$-82,197,000
Financing CF
$235,949,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.65
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-538,167,000
Inventory
—
Receivables
$60,000
ST Investments
$279,640,000
EBIT TTM
$-186,001,000
Pretax Income TTM
$-174,070,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,000,000
EBITDA
—
Free Cash Flow
$-91,454,000
Enterprise Value
$279,950,208
Total Cash
$393,223,008
Total Debt
$256,000
Shares Out
51,723,074
Trailing EPS
$-3.60
Book Value
$7.68
ROE
-48.7%
ROA
-30.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -177,534,000 | -166,308,000 | 333,169,000 | 25,945,000 | 307,224,000 | -160,588,000 |
| Dec 2024 | 0 | -94,308,000 | -80,488,000 | 274,942,000 | 17,288,000 | 257,654,000 | -70,212,000 |
| Dec 2023 | 0 | -74,590,000 | -69,333,000 | 163,098,000 | 316,291,000 | -153,193,000 | -55,842,000 |
| Dec 2022 | 0 | -36,906,000 | -36,906,000 | 182,833,000 | 267,942,000 | -85,109,000 | -43,631,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-163,735,000
OpCashFlow TTM
—
Assets (Latest)
$394,718,000
Forward EPS
$-3.62
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANL | Adlai Nortye Group Ltd. | $556.80M | $9.48 | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $559.34M | $9.40 | — |
| WVE | Wave Life Sciences, Inc. | $560.13M | $2.84 | — |
| ACRS | Aclaris Therapeutics, Inc. | $536.11M | $3.38 | — |
| CLYM | Climb Bio, Inc. | $574.46M | $9.78 | — |
News headlines (Yahoo Finance, 1h cache)
ArriVent BioPharma Reports Third Quarter 2026 Financial Results
2026-11-09 21:01 · Yahoo
ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
2026-10-27 04:02 · Yahoo
ArriVent BioPharma (AVBP) Advances ARR 217 Into Phase 1b, Is The Selloff Overdone?
2026-10-27 01:08 · Yahoo
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
2026-10-25 13:00 · Yahoo
Why ArriVent BioPharma Stock Is In Focus After Trial Failure And Legal Probe
2026-10-24 12:14 · Yahoo
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
2026-10-23 20:00 · Yahoo
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
2026-10-19 12:01 · Yahoo
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
2026-10-12 20:01 · Yahoo
Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails
2026-10-08 05:38 · Yahoo
ArriVent’s stock plummets on Phase III NSCLC trial failure
2026-10-07 14:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.